Onglyza Heart Failure Lawsuit 2026: the 27% SAVOR Finding That Ended the MDL — What’s Left?

Not as part of a mass case. The federal multidistrict litigation and the California coordinated proceedings over Onglyza both ended in rulings for the manufacturers, upheld on appeal. The science, however, is settled fact: the 16,000-patient SAVOR trial found a 27% higher risk of hospitalization for heart failure. Individual claims are still evaluated on their own facts.

Key facts

  • Onglyza is the brand name of saxagliptin, an AstraZeneca DPP-4 inhibitor — a diabetes drug class that lowers blood sugar by blocking the DPP-4 enzyme — approved by the FDA on July 31, 2009, for type 2 diabetes.
  • The SAVOR-TIMI 53 trial randomized more than 16,000 patients with type 2 diabetes; saxagliptin patients were hospitalized for heart failure at 3.5% versus 2.8% on placebo — a 27% relative increase. Results were published in the New England Journal of Medicine in October 2013.
  • April 5, 2016: the FDA issued a Drug Safety Communication adding heart-failure warnings to the labels of medicines containing saxagliptin and alogliptin — Onglyza, Kombiglyze XR, Nesina, Kazano, and Oseni.
  • The federal MDL and the California coordinated cases over Onglyza heart-failure claims ended in defense rulings, affirmed on appeal. There is no open mass case to join.
  • Generic saxagliptin, approved since 2023 and still prescribed, carries the same heart-failure warning on its label.

What Onglyza Is — and Who Takes It

Onglyza belongs to the DPP-4 inhibitor class of type 2 diabetes drugs, which work by prolonging the action of incretin hormones that tell the pancreas to release insulin after meals. It is typically prescribed when metformin alone does not control blood sugar, and it is also sold in combination with metformin as Kombiglyze XR. For years it was a routine, well-tolerated option — until a giant cardiovascular-outcomes trial produced a number nobody could ignore.

SAVOR-TIMI 53: The 16,000-Patient Trial That Started It All

After 2008, the FDA required diabetes-drug makers to prove their products did not increase cardiovascular risk, and AstraZeneca ran SAVOR-TIMI 53: more than 16,000 patients with type 2 diabetes randomized to saxagliptin or placebo. On the trial’s main composite endpoint — cardiovascular death, heart attack, or ischemic stroke — the drug passed; there was no significant difference. But buried in the secondary outcomes was the signal that defined the next decade of litigation: hospitalization for heart failure occurred in 3.5% of saxagliptin patients versus 2.8% on placebo, a 27% relative increase that the FDA later deemed valid. The trial met its formal goal and still produced the plaintiffs’ entire case — a paradox that explains much of what happened in court.

The FDA’s April 2016 Warning

On April 5, 2016, the FDA issued a Drug Safety Communication requiring heart-failure warnings on the labels of type 2 diabetes medicines containing saxagliptin or alogliptin — Onglyza, Kombiglyze XR, Nesina, Kazano, and Oseni. The agency’s language was pointed: these drugs “may increase the risk of heart failure, particularly in patients who already have heart or kidney disease,” and health professionals should consider discontinuing them in patients who develop heart failure. A second large trial, EXAMINE (alogliptin: 3.9% versus 3.3% placebo), reinforced that the signal was a class concern, not a statistical fluke. From that date forward, every prescription carried the warning the lawsuits said should have come sooner.

The Lawsuits: From Filing Wave to Defense Verdicts

Plaintiffs alleged that AstraZeneca failed to warn about the heart-failure risk and that patients suffered congestive heart failure, hospitalizations, and deaths they might have avoided with earlier knowledge — one widely cited case involved a Texas patient who developed congestive heart failure after taking Onglyza and Kombiglyze XR between 2010 and 2015. Cases were consolidated in a federal MDL and in coordinated California proceedings. Then the litigation collapsed for plaintiffs: courts ruled for the manufacturers, and the appellate courts upheld those rulings. The pattern will be familiar to anyone who followed the Invokana docket — a real FDA safety signal, years of litigation, and a defense win on the legal theories as framed.

Why the Mass Litigation Failed

It is important to be precise about what “failed” means here. No court declared saxagliptin safe for every patient; the warning remains on the label to this day. What the courts concluded was that the manufacturers’ warnings and the evidence on causation, as presented in these cases, did not support liability under the legal theories the plaintiffs pursued — and the appeals courts agreed. Mass torts are won and lost on framing as much as on facts: the same 27% number that looks damning in a headline must survive causation (proof this drug caused this patient’s heart failure, as distinct from diabetes itself, a leading cause of heart failure) and warning adequacy (proof the label said too little, too late) in front of judges applying strict evidentiary rules. Here, those hurdles proved decisive — a dynamic also visible in the Xeljanz litigation, where a boxed warning reshaped but did not end the legal fight.

What Claims Can Still Be Filed in 2026

The end of the MDL does not mean the end of all claims; it means the end of the coordinated mass vehicle. Individual lawsuits are still evaluated on their own facts — particularly claims that turn on a specific prescriber’s management of a specific patient’s heart-failure risk, rather than on the label language the MDL courts already adjudicated. The practical constraints are severe: time limits for drug-injury claims are short and vary by state and by defendant type, evidence must connect this prescription to this hospitalization, and generic-era prescriptions raise additional legal questions. Anyone considering a claim needs a lawyer’s assessment of their own dates and records, quickly. The broader lesson of the Actos settlement history applies here too: in drug litigation, timing and documentation decide more cases than outrage does.

If You Take Saxagliptin Today

Millions of prescriptions for saxagliptin — brand and generic — are still written, and the drug remains an effective glucose-lowering option for many patients. Do not stop taking a prescribed diabetes medication abruptly; uncontrolled blood sugar carries its own serious risks. Instead, know the warning signs the label flags: new or worsening shortness of breath, unusual fatigue, and swelling in the legs, ankles, or feet — especially if you have a history of heart failure or kidney disease. Raise any of these with your doctor promptly, and make sure every prescriber managing your care knows you take a DPP-4 inhibitor with a heart-failure warning.

Who Benefits From This — and Who Does Not

The Onglyza story splits in two: the mass litigation ended in rulings for the manufacturers, upheld on appeal, while the heart-failure warning from the April 2016 FDA communication remains on the label — so what helps readers now is knowing the warning signs and how individual claims are judged.

Who benefits:

  • Patients who took saxagliptin and were hospitalized for heart failure: Individual lawsuits are still evaluated on their own facts, particularly claims turning on a specific prescriber's warnings, even though no mass case remains to join.
  • People currently taking saxagliptin, brand or generic: Knowing the label's warning signs — shortness of breath, unusual fatigue or weakness, and swelling in the legs, ankles, or feet — lets you seek care promptly, especially if you already have heart or kidney disease.
  • Readers weighing the SAVOR evidence for themselves: The trial's numbers are public: hospitalization for heart failure occurred in 3.5% of the saxagliptin group versus 2.8% on placebo, a 27% relative increase in a trial of more than 16,000 patients.

Who benefits little or not at all:

  • People hoping to join a mass Onglyza case: The federal multidistrict litigation and the California coordinated proceedings both ended in rulings for the manufacturers, upheld on appeal, so there is no open group litigation to join.
  • Anyone planning to stop a prescribed diabetes medication on the basis of this article: The article warns not to stop taking a prescribed diabetes medication abruptly; any change belongs in a conversation with your physician.
  • People who read the failed mass case as proof the drug is safe for everyone: No court declared saxagliptin safe for every patient; the heart-failure warning remains on the label to this day.

Related reading: Taxotere Lawsuit 2026: 2,500 Cases Settled, Then the May 2025 Ruling — Can You Still File?.

Frequently Asked Questions

Can I still join the Onglyza lawsuit in 2026?

Not as part of a mass case. The federal MDL and the California coordinated proceedings both ended in rulings for the manufacturers, upheld on appeal, so there is no open group litigation to join. Individual claims — particularly ones turning on a specific prescriber’s handling of heart-failure risk — are still evaluated on their own facts, subject to strict time limits.

What did the SAVOR trial actually find?

SAVOR-TIMI 53 randomized more than 16,000 patients with type 2 diabetes to saxagliptin or placebo. Hospitalization for heart failure occurred in 3.5% of the saxagliptin group versus 2.8% on placebo — a 27% relative increase — while the trial’s main composite endpoint of cardiovascular death, heart attack, and stroke showed no significant difference.

Does generic saxagliptin carry the same heart-failure warning?

Yes. Generic saxagliptin and saxagliptin-with-metformin products, approved since 2023 and still prescribed, carry the same heart-failure warning on their labels as brand-name Onglyza.

What are the warning signs of heart failure to watch for?

The label highlights shortness of breath, unusual fatigue or weakness, and swelling in the legs, ankles, or feet — especially in patients who already have heart or kidney disease. Anyone experiencing these symptoms should seek medical care promptly; do not stop a prescribed diabetes drug abruptly without talking to your doctor.

Who benefits from the Onglyza story — and who does not?

Patients hospitalized for heart failure while taking saxagliptin may still have an individual claim evaluated on its own facts, and current saxagliptin users benefit from knowing the label's warning signs. Nobody benefits by expecting a mass case to join, since both coordinated proceedings ended for the manufacturers, and nobody should stop a prescribed diabetes drug abruptly because of this article.

How do I start an individual Onglyza claim?

Collect your prescription history for saxagliptin, records of any heart-failure hospitalization, and anything your prescriber told you about heart-failure risk, then ask an attorney to evaluate the individual facts, since mass proceedings are closed. Keep taking any prescribed medication unless your physician advises otherwise, and seek care promptly for shortness of breath, unusual fatigue, or leg swelling.

This article is general information about litigation history and publicly reported court developments. It is not legal advice and not medical advice. Deadlines and claim rules vary by state and by case; speak with a qualified attorney promptly if you believe you were affected.

For plain-language explainers on how drug-injury cases work, see the Problem Solved channel on YouTube.

Watch on YouTube

Problem Solved on YouTube